oral abstract - Robuta Search

https://umaine.edu/mitchellcenter/2025-oral-abstract-submissions/ 2025 Oral Abstract Submissions - Senator George J. Mitchell Center for Sustainability Solutions -... george j mitchell center for sustainability oral abstract https://www.biospace.com/press-releases/applied-therapeutics-announces-acceptance-of-late-breaking-abstract-for-oral-presentation-at-the-peripheral-nerve-society-2025-annual-meeting Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the... https://www.biospace.com/innovate-3-late-breaking-abstract-selected-as-a-best-oral-presentation-at-esgo INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO - BioSpace Mar 11, 2024 - Novocure announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3... https://www.taiwannews.com.tw/news/6213532 Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for... | Oct. 3, 2025 21:30 https://www.omicsonline.org/peer-reviewed/oral-health-of-children-and-adolescents-in-da-nangp-30070.html Oral Health of Children and Adolescents in Da Nang | OMICS International | Abstract Oral Health of Children and Adolescents in Da Nang Abstract. children and adolescents in da nang oral health https://www.omicsonline.org/peer-reviewed/impaired-glucose-tolerance-and-its-association-to-oral-cancerp-32305.html Impaired Glucose Tolerance and its Association to Oral Cancer | OMICS International | Abstract Impaired Glucose Tolerance and its Association to Oral Cancer Abstract. impaired glucose tolerance https://www.globenewswire.com/news-release/2025/04/21/3064621/0/en/IMUNON-Announces-IMNN-001-Abstract-Accepted-for-Oral-Presentation-at-2025-ASCO-Annual-Meeting.html IMUNON Announces IMNN-001 Abstract Accepted for Oral Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial... imunon announces 001 abstract accepted https://www.businesswire.com/news/home/20231025702369/en/BioMimetix-Announces-Acceptance-of-Late-Breaking-Abstract-and-Oral-Presentation-of-BMX-001-Clinical-Data-at-the-2023-Society-for-Neuro-Oncology-Annual-Meeting BioMimetix Announces Acceptance of Late-Breaking Abstract and Oral Presentation of BMX-001 Clinical... BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today annou...